Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by TheStreet from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

The analysts wrote, “Vertex Pharmaceuticals (VRTX) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its increase in stock price during the past year, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company’s earnings per share.”

Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 1.73% on Wednesday, hitting $96.68. The stock had a trading volume of 906,455 shares. Vertex Pharmaceuticals has a 1-year low of $58.06 and a 1-year high of $99.58. The stock’s 50-day moving average is $77.44 and its 200-day moving average is $75.35. The company’s market cap is $22.835 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Thursday, May 1st. The company reported ($0.65) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.03 earnings per share. Vertex Pharmaceuticals’s revenue was down 63.9% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals will post $-2.87 EPS for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Elaine Ullian sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $95.21, for a total transaction of $476,050.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. They now have a $102.00 price target on the stock. Separately, analysts at Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday. Finally, analysts at Goldman Sachs raised their price target on shares of Vertex Pharmaceuticals to $109.00 in a research note on Wednesday, June 25th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $102.50.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.